NCP 112
Alternative Names: NCP-112Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator DongKoo Bio&Pharma
- Developer DongKoo Bio&Pharma; Huons
- Class Eye disorder therapies; Peptides; Skin disorder therapies
- Mechanism of Action FPR2 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Xerophthalmia
- No development reported Atopic dermatitis
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Atopic-dermatitis(In volunteers) in South Korea (Topical, Gel)
- 11 Jul 2024 Phase-I clinical trials in Xerophthalmia (In volunteers) in South Korea (Opthalmic) (NCT06263998)
- 22 Feb 2024 Huons plans a phase I trial for (In volunteers, In adults) in June 2024 (NCT06263998)